1. PSA and bone scintigraphy.
- Author
-
Modoni S, Calò E, Nardella G, Ritrovato G, and Frusciante V
- Subjects
- Adenocarcinoma blood, Adenocarcinoma diagnosis, Adenocarcinoma diagnostic imaging, Adult, Aged, Aged, 80 and over, Blood Chemical Analysis economics, Bone Neoplasms blood, Bone Neoplasms diagnosis, Bone Neoplasms diagnostic imaging, Combined Modality Therapy, Cost Control, Diagnostic Tests, Routine economics, Evaluation Studies as Topic, Humans, Male, Middle Aged, Predictive Value of Tests, Prostatectomy, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery, Radionuclide Imaging economics, Radiotherapy, Adjuvant, Sensitivity and Specificity, Soft Tissue Neoplasms blood, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms diagnostic imaging, Soft Tissue Neoplasms secondary, Adenocarcinoma secondary, Biomarkers, Tumor blood, Bone Neoplasms secondary, Bone and Bones diagnostic imaging, Prostate-Specific Antigen blood, Prostatic Neoplasms blood
- Abstract
The authors evaluate the role of prostate specific antigen (PSA) and bone scintigraphy in the follow-up of radical prostatectomy-treated and radiotherapy-treated patients. 784 patients were evaluated by simultaneous PSA assay and bone scans. The correlation between PSA levels and extension of bone metastases was good. The frequency of extraskeletal metastases was low: only 13 patients had soft tissue metastases without bone involvement and 33/138 patients with bone metastases had also extraskeletal metastases. The results underline the importance of PSA and the possibility to omit bone scan when the PSA level is below 8 ng/ml in patients who did not undergo anti-androgenic treatments.
- Published
- 1997
- Full Text
- View/download PDF